Surprisingly few new parents enlist in study to have baby's genome sequenced
By Jocelyn Kaiser,
Science Magazine
| 10. 19. 2016
One of the first studies to explore the idea of routinely sequencing the genes of newborns to help guide their health care has run into an unexpected road bump: Few parents approached are interested in having their baby’s genome profiled.
When Robert Green, a geneticist at the Harvard University–affiliated Brigham and Women’s Hospital in Boston, and co-workers began planning to sequence babies about 4 years ago, they surveyed more than 500 parents of healthy newborns. Nearly half declared they would be “very” or “extremely” interested and another 37% said “somewhat.” But since their actual BabySeq Project began last year in May, only about 7% of more than 2400 couples approached so far have agreed to participate, says Green, who co-leads BabySeq with Alan Beggs of Boston Children's Hospital. That “very surprising” figure is the same both for parents of very sick infants and those with healthy babies, he adds.
BabySeq is one of four projects funded by the National Institutes of Health (NIH) 3 years ago to probe the risks and benefits of sequencing newborns’ DNA and compare the results to conventional newborn...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...